JTK-109

• CAT Number: I007394
• CAS Number: 480462-62-2
• Molecular Formula: C37H34Cl2FN3O4
• Molecular Weight: 674.59
• Purity: ≥95%
• Synonyms: JTK-109; JTK 109; JTK109;2-(4-((4/’-chloro-4-(2-oxopyrrolidin-1-yl)-[1,1/’-biphenyl]-2-yl)methoxy)-2-fluorophenyl)-1-cyclohexyl-1H-benzo[d]imidazole-5-carboxylic acid hydrochloride
• Target: NS5B Inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 2-[4-[[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)phenyl]methoxy]-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid
• InChI: InChI=1S/C37H33ClFN3O4/c38-26-11-8-23(9-12-26)30-15-13-28(41-18-4-7-35(41)43)19-25(30)22-46-29-14-16-31(32(39)21-29)36-40-33-20-24(37(44)45)10-17-34(33)42(36)27-5-2-1-3-6-27/h8-17,19-21,27H,1-7,18,22H2,(H,44,45)
• InChIKey: NIBYCXOKANETJM-UHFFFAOYSA-N
• SMILES: C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)O)N=C2C4=C(C=C(C=C4)OCC5=C(C=CC(=C5)N6CCCC6=O)C7=CC=C(C=C7)Cl)F

JTK-109（Cat No.:I007394）is a small molecule inhibitor developed to target Janus kinase 3 (JAK3), a key enzyme involved in immune cell signaling. JAK3 plays a critical role in the immune response, particularly in T-cell activation and cytokine production. By selectively inhibiting JAK3, JTK-109 modulates immune system activity, which makes it a promising candidate for treating autoimmune diseases and inflammatory conditions. It has shown potential in preclinical studies for diseases such as rheumatoid arthritis and inflammatory bowel disease. Ongoing research is focused on evaluating its safety, efficacy, and therapeutic potential in clinical settings.

Reference

1:J Med Chem. 2006 Jul 27;49(15):4721-36. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.Hirashima S,Suzuki T,Ishida T,Noji S,Yata S,Ando I,Komatsu M,Ikeda S,Hashimoto H, PMID: 16854079 DOI: 10.1021/jm060269e Abstract: Following the discovery of a new series of benzimidazole derivatives bearing a diarylmethyl group as inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase (HCV NS5B RdRp),1,2 we extended the structure-activity relationship (SAR) study to analogues bearing a substituted biphenyl group and succeeded in a significant advancement of activity. Starting from compound 1, optimization of the A, B, and C rings afforded potent inhibitors with low nanomolar potency against genotype 1b NS5B. The compounds, which have a substituent with a carbonyl function at the 4-position of the B-ring, efficiently blocked subgenomic viral RNA replication in the replicon cell assay at low submicromolar concentrations. Among the new compounds, compound 10n (JTK-109) exhibited favorable pharmacokinetic profiles, high selectivity for NS5B, and good safety profiles, suggesting the potential for a clinical candidate in the treatment of hepatitis C.